| Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance |
Aurinia Pharmaceuticals Inc. AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents. |
benzinga.com |
2025-05-12 16:56:52 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - President and CEO Joe Miller - CFO Greg Keenan - CMO Conference Call Participants Stacy Ku - TD Cowen Maury Raycroft - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Operator Greetings, and welcome to the Aurinia Pharmaceuticals Inc. Q1 2025 Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-12 15:04:13 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates |
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.03 per share a year ago. |
zacks.com |
2025-05-12 12:10:41 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025. |
businesswire.com |
2025-05-12 10:00:00 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025. |
businesswire.com |
2025-05-05 10:00:00 |
Czytaj oryginał (ang.) |
| Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Glass Lewis recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting. |
businesswire.com |
2025-04-30 10:00:00 |
Czytaj oryginał (ang.) |
| ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--ISS recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting. |
businesswire.com |
2025-04-29 10:00:00 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth |
AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 earnings represent an opportunity to confirm that trend. AUPH is also expected to report the first clinical data from AUR200 in Q2 '25, which might allow the opportunity for the company to one day grow beyond revenues from Lupkynis. |
seekingalpha.com |
2025-04-26 14:54:05 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms |
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio. |
zacks.com |
2025-04-23 14:35:35 |
Czytaj oryginał (ang.) |
| Insiders Are Loading Up on These 4 Biotech Stocks Now |
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so. |
247wallst.com |
2025-03-11 10:45:13 |
Czytaj oryginał (ang.) |
| Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations |
On Thursday, Aurinia Pharmaceuticals Inc AUPH reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents. |
benzinga.com |
2025-02-27 16:11:21 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications and Investor Relations Peter Greenleaf - President, Chief Executive Officer and Director Joe Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Vishwesh Shah - TD Cowen Olivia Brayer - Cantor Fitzgerald Farzin Haque - Jefferies Will Soghikian - Leerink Partners Ed Arce - H.C. Wainwright Operator Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full-Year 2024 Earnings Call. |
seekingalpha.com |
2025-02-27 12:32:52 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates |
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2025-02-27 10:10:40 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress. |
businesswire.com |
2025-02-27 08:00:00 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals: There's Still Time For Sales Growth |
AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appears achievable, with $158.6M already reported and Q4 typically outperforming Q3. Potential competitors in lupus nephritis and even in systemic lupus erythematosus include Roche and Biogen. |
seekingalpha.com |
2025-02-21 18:09:35 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025. |
businesswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| Aurinia (AUPH) Upgraded to Buy: Here's Why |
Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-01-22 15:00:36 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks With Notable Insider Buying |
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners. |
seekingalpha.com |
2025-01-22 14:29:06 |
Czytaj oryginał (ang.) |
| Insiders Are Loving These 6 Stocks Right Now |
The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly. |
247wallst.com |
2024-12-15 10:20:56 |
Czytaj oryginał (ang.) |
| Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis. |
businesswire.com |
2024-11-18 19:53:00 |
Czytaj oryginał (ang.) |
| Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), and reinforce the clinical importance of LUPKYNIS® (vo. |
businesswire.com |
2024-11-15 08:00:00 |
Czytaj oryginał (ang.) |
| Aurinia to Participate in Jefferies London Healthcare Conference |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Jefferies London Healthcare Conference. |
businesswire.com |
2024-11-14 08:00:00 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon |
Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance sheet and should become increasingly profitable in coming years. |
seekingalpha.com |
2024-11-08 14:15:31 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript |
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Stacy Ku - TD Cowen Maurice Raycroft - Jefferies Olivia Brayer - Cantor Fitzgerald Will Soghikian - Leerink Partners Operator Greetings, and welcome to Aurinia Pharmaceuticals Third Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. |
seekingalpha.com |
2024-11-07 13:44:10 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates |
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2024-11-07 10:40:22 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth. |
businesswire.com |
2024-11-07 08:10:00 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months ended September 30, 2024. With continued strong commercial execution, the Company achieved significant year-over-year growth in total net revenue and net product revenue and $17.0 million in cash flow from operations in the third quarter. Having achieved $158.6 million in net product revenue for the nin. |
businesswire.com |
2024-11-07 08:00:00 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024. |
businesswire.com |
2024-10-30 18:05:00 |
Czytaj oryginał (ang.) |
| Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at ASN Kidney Week 2024. |
businesswire.com |
2024-10-11 10:00:00 |
Czytaj oryginał (ang.) |
| 3 Small Biotech Stocks With The 'Big Mo' Right Now |
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below. |
seekingalpha.com |
2024-09-19 16:54:05 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment |
Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. The partnership with Otsuka Pharmaceutical supports Aurinia's international expansion into European and Asian markets. AUR200, now in Phase 1 trials, could be a significant future value driver targeting autoimmune diseases. |
seekingalpha.com |
2024-09-19 11:55:29 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals: This Recovery Can Continue |
Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales. AUPH is developing AUR200, with a phase 1 trial underway allowing it to diversify beyond Lupkynis. The Company reported a $722K net income for Q2'24, up from a $10.7M net loss in Q1'24. |
seekingalpha.com |
2024-09-18 08:41:39 |
Czytaj oryginał (ang.) |
| Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference. |
businesswire.com |
2024-09-13 10:00:00 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript |
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Joseph Schwartz - Leerink Partners Stacy Ku - TD Cowen Ed Arce - H.C. Wainwright & Co. Operator Good day, ladies and gentlemen. |
seekingalpha.com |
2024-08-01 17:52:05 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates |
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.08 per share a year ago. |
zacks.com |
2024-08-01 12:10:43 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 |
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024. |
businesswire.com |
2024-07-19 10:00:00 |
Czytaj oryginał (ang.) |
| Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock? |
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-07-12 09:41:44 |
Czytaj oryginał (ang.) |
| Aurinia Pharmaceuticals Appears Undervalued |
Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021. Management is focusing solely on driving Lupkynis sales and cutting costs by laying off 25% of its sales force and discontinuing other programs. With positive cash flow expected soon, a $150 million share repurchase plan, and strong financials, Aurinia is undervalued and worth considering for investment. |
seekingalpha.com |
2024-07-05 18:10:21 |
Czytaj oryginał (ang.) |